Drug Profile
AVA 001
Alternative Names: AVA-101; AVA-201; rAAV.sFlt-1Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Avalanche Biotechnologies
- Developer Adverum Biotechnologies
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration
Most Recent Events
- 23 Feb 2023 Discontinued - Phase-II for Wet age-related macular degeneration (In the elderly) in Australia (Intraocular) (Adverum Biotechnologies pipeline; February 2023).
- 23 Feb 2023 Discontinued - Preclinical for Diabetic macular oedema in USA (Intraocular) (Adverum Biotechnologies pipeline; February 2023).
- 23 Feb 2023 Discontinued - Preclinical for Retinal vein occlusion in USA (Intraocular) (Adverum Biotechnologies pipeline; February 2023).